Synergy Pharma (SGYP) to Present at Two Upcoming Investor Conferences

NEW YORK, Feb. 22, 2013 (GLOBE NEWSWIRE) — Synergy Pharmaceuticals, Inc. (Nasdaq:SGYP), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, announced today that President and CEO Gary S. Jacob, Ph.D., will be presenting a corporate overview at two healthcare conferences in New York this month.

• Citi 2013 Global Healthcare Conference on Monday, February 25th, 2013 at 10:20am at the Hilton New York Hotel.
• RBC Capital Markets Healthcare Conference on Tuesday, February 26th, 2013 at 4:35pm at the New York Palace Hotel.

Live audio webcasts of both presentations will be available under the investor relations section of Synergy’s website at www.synergypharma.com. Replays of the presentations will be available for 60 days afterward.

About Synergy Pharmaceuticals, Inc.

Synergy is a biopharmaceutical company focused on the development of new drugs to treat gastrointestinal disorders and diseases. Synergy’s lead proprietary drug candidate, plecanatide, is a synthetic analog of the human gastrointestinal hormone uroguanylin, and functions by activating the guanylate cyclase C receptor on epithelial cells of the GI tract. Synergy completed a positive Phase I study of plecanatide in healthy volunteers, and positive Phase IIa and Phase IIb/III clinical trials in patients with chronic idiopathic constipation (CIC). Detailed positive findings from a recently completed 951 patient CIC clinical trial will be presented at a major scientific meeting this year. Synergy is also developing plecanatide for the treatment of irritable bowel syndrome with constipation (IBS-C), having initiated the first trial in IBS-C patients in late 2012. Synergy’s second GC-C agonist, SP-333, is in clinical development to treat inflammatory bowel diseases, and has recently completed its first Phase I trial in healthy volunteers. More information is available at http://www.synergypharma.com

CONTACT: Media Contact: Janet Skidmore
         Office:  215-658-4915
         Mobile:  215-429-2917
         skidmorecomm@earthlink.net

         Investor Contact: Danielle Spangler
         The Trout Group
         synergy@troutgroup.com
         (646) 378-2924